Characteristics and management of patients with idiopathic pulmonary fibrosis treated with pirfenidone capsule or tablet formulation
Abstract
Introduction: Pirfenidone is indicated in the treatment of idiopathic pulmonary fibrosis (IPF) and is now available in tablets instead of capsules.
Objective: To describe tolerance, discontinuation and switch rate of capsules/tablets of pirfenidone in France.
Methods: Retrospective analysis of the RaDiCo-ILD cohort in patients (pts) who received at least one dose of pirfenidone (2017-2019).
Results: A total of 288 pts were treated with pirfenidone including 162 who newly initiated pirfenidone. There were no meaningful differences between the baseline characteristics (gender, age at inclusion/at diagnosis) by formulation of the 256 pts treated with pirfenidone during the potential switch. A total of 44.9% (95% CI 38.8-51.0) pts switched from capsule to tablet formulation and 4.7% from tablet to capsule. Overall, mean treatment duration was 21.5 months (±18.7) and median (Q1; Q3) was 16.2 [6.3; 29.3] with a mean dose of 2106.7 (±460.7)mg/day; 119/256 pts (46.5%) discontinued treatment, 81/119 pts (68.1%) for intolerance and 21/119 pts (10.1%) for ineffectiveness; as shown in the figure there were globally less discontinuations in the tablets and switch groups vs. the capsules only group.
Conclusion: Our study shows real-life data in patients with IPF treated with or switching between the two dosage forms of pirfenidone (capsule or tablet).
Origin : Files produced by the author(s)